关于药物标相互作用的深度表示学习算法,用于选针对阿尔茨海默病的新药候选药物
Xin Yuan1, Lihui Gao1, Yonglin Peng1
1School of Biomedical Engineering, Tianjin Medical University, Tianjin, China.
Artificial intelligence in medicine
|November 20, 2025
概括
这项研究介绍了药物向相互作用预测 (DTIP),这是一个机器学习工具,用于找到新的阿尔茨海默病 (AD) 药物. DTIP确定了292种潜在的AD治疗候选药物,提供了新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,治疗方法有限.
- 目前的治疗方法可以缓解症状,但不能阻止疾病的进展,因此需要新的治疗策略.
研究的目的:
- 开发和应用一种机器学习方法,即药物向相互作用预测 (DTIP),用于识别阿尔茨海默病的新药候选药物.
- 利用药物向相互作用 (DTI) 数据来预测AD的潜在治疗剂.
主要方法:
- 开发了DTIP,一种使用Skip-gram的机器学习模型,从已知的DTI数据中学习药物目标关系.
- 编译了917个AD风险基因,并使用DTIP确定了292种潜在的候选药物.
- 通过分子对接 (AutoDock Vina) 和逆转基因组丰富分析 (IGSEA) 验证的候选药物.
主要成果:
- DTIP成功预测了阿尔茨海默病的292种潜在候选药物.
- 几种已识别的药物,包括人类C1-雌激酶抑制剂,氨酸和达沙替尼,在阿尔茨海默氏症治疗中表现有前途.
- 该研究提供了对阿尔茨海默氏症分子机制的见解,并确定了潜在的治疗剂.
结论:
- DTIP方法是一种系统和多功能方法,用于发现针对阿尔茨海默氏症等复杂疾病的新药.
- 已识别的候选药物需要进一步调查它们在治疗阿尔茨海默病中的有效性.
- 这种计算策略可以广泛应用于加速各种神经系统疾病的药物发现.
相关概念视频
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Targets for Drug Action: Overview
10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K


